Introduction
Mongolia is one of the seven countries with a high burden of tuberculosis (TB) in the western Pacific Region [1] . Doubling of case notification rates between the years 1990 and 2007, from 79 to 166 per 100,000 population, presents a serious concern for the Mongolian health authority. The mortality rate of TB was 2.5 per 100,000 population in 2007 [2] . In 2008, the failure rate among new smear-positive cases was 6.2%, which was six times higher than the region's average. Previous studies showed a low rate of multi-drug resistant tuberculosis (MDR-TB) among new cases [1.4% (95% CI 0.7-1.6)], whereas, the rate was significantly higher [27.5% (95% CI 21.8-34.1)] in retreatment cases [3] . Importantly, around 24% of emerged 2212-5531/$ -see front matter Ó 2012 Asian-African Society for Mycobacteriology. All rights reserved. doi:10.1016/j.ijmyco.2012.01.007 MDR-TB patients were not detected in a timely manner. Therefore, rapid and accurate detection of resistant strains is essential for both efficient treatment and control strategies. Generally, drug susceptibility testing (DST) is performed by the conventional method, which takes several weeks to yield a result. Today, advances in molecular technology have provided rapid systems that shorten the time needed for MDR-TB detection. Among them, the Genotype â MTBDR plus assay can identify the resistant strains within 1 day. The MTBDR plus is a polymerase chain reaction (PCR) amplification and solid-phase reverse assay which detects mutations in the rpoB for rifampicin (RIF) resistance, the katG for highlevel isoniazid (INH) resistance, and the inhA for low-level INH resistance directly from smear-positive sputum [4] . Thus, this method needs to be studied particularly in the developing world. The aim of this study was to assess the diagnostic accuracy of a molecular line probe assay (MTBDR plus assay) to rapidly detect mutations associated with RIF and INH in culture specimens and directly in smear-positive clinical specimens collected from previously treated TB patients in Mongolia.
Methods and materials

Study setting and population
This study was conducted at the National Reference TB Laboratory located at the National Center for Communicable Diseases, Ulaanbaatar (UB). This laboratory serves a population of approximately 1 million people in the capital city of Ulaanbaatar. All diagnostic centers in eight districts of UB participated in the survey. The calculation of the sample size followed the principles outlined in the WHO/IUATLD guidelines [5] . Participant recruitment was based on the results of sputum smear examination for acid-fast bacillus smear and culture and sensitivity (AFB). Specimens with culture negative results, contamination, or growth with other Mycobacterium spp. were excluded from further investigation. Overall, 180 smear-positive specimens from relapse, failure or default of the treatment outcomes were included in this study.
Specimen
Two specimens with the highest count of bacilli upon ZiehlNeelsen examination were submitted for culture and susceptibility testing on solid media and direct MTBDR plus tests. Specimens were processed by the conventional N-acetyl-Lcysteine-NaOH method (1% final NaOH concentration). After decontamination, the concentrated sediments were suspended in 1.0-1.5 ml sterile phosphate buffer (pH 7.0) and smears were prepared by the Ziehl-Neelsen staining method. After inoculation onto solid medium, the leftover sediments of the decontaminated sputum specimens were stored at À20°C. The leftover sediments of the chosen specimens were thawed and used for MTBDR plus testing. Sample volumes of 500 microliters (ll) were centrifuged for 15 min at 10,000g, the supernatant was discarded, and the pellet was re-suspended in100 ll of distilled water. Subsequently, the suspension was boiled for 20 min and incubated in a sonic water bath at room temperature for 15 min [6] .
Drug susceptibility testing
Sputum smear microscopy positive samples were cultured on Lö wenstein-Jensen (LJ) culture medium. Mycobacterium tuberculosis complex was identified by culturing on LJ medium containing p-nitrobenzoic acid. Drug susceptibility testing (DST) was performed by proportion method on LJ medium impregnated with isoniazid, rifampicin, streptomycin, and ethambutol according to the proportion method as recommended by WHO/IUATL [7] .
GenoType â MTBDRplus assay
The strip assay was performed as recommended by the manufacturer [6] . Briefly, for amplification, 35 ll of a primer-nucleotide mixture (provided with the kit), 5 ll of buffer containing 2.5 mM MgCl 2 , 1.25 U Taq DNA polymerase, and 5 ll of the preparation of mycobacterial DNA in a final volume of 50 ll were used. The amplification protocol consisted of 15 min of denaturing at 95°C; 10 cycles comprising 30 s at 95°C and 120 s at 58°C; an additional 20 cycles comprising 25 s at 95°C, 40 s at 53°C, and 40 s at 70°C; and a final extension at 70°C for 8 min. Hybridization and detection were performed in a shaking incubator, and this procedure was performed at 45°C for 30 min, followed by two washing steps. Steps taken to avoid amplicon contamination were manual pipetting of the amplicon, use of separate wells and tubes for each strip, and extensive rinsing after each use. After a final washing, strips were air dried and fixed on paper. For the sputum specimens, an altered amplification protocol was applied which consisted of 15 min of denaturing at 95°C; 10 cycles comprising 30 s at 95°C and 120 s at 58°C; an additional 30 cycles comprising 25 s at 95°C, 40 s at 53°C, and 40 s at 70°C; and a final extension at 70°C for 8 min. Hybridization and detection were performed as described above. Each strip consists of 27 reaction zones (bands), including six controls (conjugate, amplification, M. tuberculosis complex, rpoB, katG, and inhA controls), eight rpoB wild-type (WT) and four mutant probes (rpoB MUT D516V, rpoB MUT H526Y, rpoB MUT H526D, and rpoB MUT S531L), one katG wild-type and two mutant probes (katG MUT T1S315T1 and MUT T2S315T2), and two inhA WTand four mutant probes (inhA MUT1C15T, inhAMU-T2A16G, inhA MUT3A TBC, inhA TBA) (Fig. 1) . Results were interpreted according to the manufacturer's instructions.
Laboratory quality control
Procedures for external quality assurance for smear and culture were based on the WHO guidelines [5] . The National Reference Laboratory before the start of the survey had participated in external quality assurance proficiency tests. The efficiency for determining INH and RIF resistance in 2009 was 100% using the conventional proportion method as a standard by SRL of Research Institute of Tuberculosis, Japan (RIT) [7] . The efficiency for identifying INH-and RIF-resistant strains using MTBDR plus assay was 99.0% and 91.6%, respectively, considering the conventional proportion DST as a standard.
Data analysis
The data were analyzed using SPSS 17.0 software. Sensitivity, specificity, positive predictive and negative predictive values of the molecular line probe assay were assessed compared with conventional testing [8] . Reporting time was calculated from the date of inoculation and the date of reporting of the conventional DST result or the date of availability of the molecular line probe assay.
Results
Study subjects
The study covered 218 MDR-TB subjects within the age range of 14-75 years old from 8 districts of UB registered from 1 July 2009 to 30 May 2010. One hundred twenty-seven (127; 58.3%) were males and the remaining were female (91; 41.7%). A total of 68 patients with exclusive criteria were excluded from the study. A total of 150 patients with both results of MTBDR assay and conventional DST are subjects of this analysis.
GenoType MTBDRplus testing from smear-positive sputum
The GenoType â M. tuberculosis drug resistance first line (MTBDRplus) assay (Hain Life-science, Nehren, Germany) was used in the study. As shown in Table 1 , of the total specimens with conventional DST results, 75 (50.0%) were fully susceptible strains, 61 (40.7%) were MDR, 5 (3.3%) were RIF mono-resistant, 10 (6.7%) were INH mono-resistant. The results were comparatively analyzed with MTBDR plus assay. A total of three discrepant results between LPA and DST were observed. For detection of discrepancies, the samples were compared with DNA sequencing results. The overall, sensitivity, specificity and positive and negative predictive values of the specimens with rapid and conventional results are shown in Table 2 . Comparing the different banding patterns in drugresistant isolates, including MDR, RIF-mono-resistant and INH-mono-resistant strains showed S531L mutation (MUT3 band) was more frequent and occurred in all RIF-resistant strains (78.8%). Of all INH-resistant strains, 33.8% (37.7% of MDR strains and 10% of INH-mono-resistant strains) had a mutation (MUT1) in the katG, and 67.6% (63.9% of MDR strains and 90% of INH-mono-resistant strains) had a mutation (MUT1) in the inhA. Three strains had mutations in both the katG and inhA. Nine of 10 (90%) INH-mono-resistant strains were detected by the presence of a mutation in inhA only (Table 3 ).
Discussion
The prevalence of identified MDR-TB cases was higher (40, 7%) in Mongolian retreated cases. Using MTBDRplus assay, most common mutations were rapidly and specifically detected along with their resistance not only to RIF, but also to INH in M. tuberculosis isolates (Tables 2 and 3 ). The probes used in this assay combine targeting the 81-bp ''hot-spot'' region in the rpoB gene, and two mutations at position 315 of the katG gene. Mutations affecting this codon are responsible for INH resistance in 60% of the cases worldwide [4] . In this current research, of all INH-resistant strains, 33.8% (37.7% of MDR strains and 10% of INH-mono-resistant strains) had a mutation of MUT1 in the katG. High frequency of mutations were found in accordance with most available reports at codons 531, 526, and 516. Although a high frequency of S531L mutation (MUT3 band) was observed in all RIF-resistant strains (83.6% of MDR), other mutations in the 530-533 regions also occurred; as detected by the lack of binding to the WT8 probe in the absence of S531L mutation. Based on previous review literature, frequencies of katG mutation among INH resistant M. tuberculosis isolates in three South American countries were as follows: Brazil (81.3%), Peru (82.4%) and Argentina (71.4%). In contrast, the frequencies for the katG S315T mutation in INH resistant M. tuberculosis isolates for patients diagnosed in Kuwait and the Netherlands (65% and 55%, respectively) was lower than what was described in Russia (95%). Mutations in the inhA promoter region was variable (15-35%) among INH-resistant M. tuberculosis strains that were collected from the same geographical region [9] . In this study, mutations in the promoter region of the inhA gene played a major role (67.6% [63.9% of MDR strains and 90% of INH-mono-resistant strains]). Based on this finding, inhA mutation may increase the capability of predicting INH resistance. At present, the manual method was used for the GenoType â MTBDRplus assay, which needs one day for amplification and another day for hybridization. Therefore, it will take two to three days to interpret the results.
Conclusions
Molecular-based rapid MDR screening with the GenoType â MTBDRplus test can be routinely used in a reference laboratory setting when rapid sensitivity testing is required for the proper management of patients or for the contacts of drug resistant cases. However, because only some of the mutations are targeted, this molecular test cannot be considered to perform alone in the laboratory.
